Inmune Bio Inc. · NASDAQ:INMB
Inmune Bio — Technical Presentation (January 2021)
21 slides from Inmune Bio's technical presentation, Jan 21, 2021
Slide 1: Harnessing the Power of the Innate Immune System
HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating an Innate Immune Response Against Diseases IN MB XPro1595 Alzheimer’s KOL event Jan 21, 2021
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation contains “forward - looking statements” Forward - looking statements reflect our current view about future events . When used in this presentation, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of the
Slide 3: Phase 1b Trial in Alzheimer's: Design
DESIGN ▪ Multiple dosing cohorts ▪ Weekly XPro1595 Œ SubQ injections for 3 months ▪ Biomarkers of neuro inflammation at 0 and 12 weeks Inclusion ▪ AD Diagnosis ▪ Biomarkers of inflammation (CRP, ESR, HgbA1C, APOE4) STUDY GOAL Demonstrate peripheral administration of XPro1595 reduces biomarkers of ne
Slide 4: Demographics of patients that have completed weeks
Demographics of patients that have completed 12 weeks Cohort 1 XPro1595 0.3 mg/kg (N=3) Cohort 2 XPro1595 1.0 mg/kg (N=6) Total (N=9) Mean Age (SD) Years 73 (62, 71, 86) 65 (60 - 71) 67.9 (62 - 80) Gender Male 1 (33.3%) 3 (50%) 4 (44%) Female 2 (66.7%) 3 (50%) 5 (56%) Ethnicity Not Hispanic or Latin
Slide 5: Patient status
Patient status ▪ 9 patients have completed the 12 - week study ▪ 6 (all high dose) enrolled into the extension study ▪ 3 patients completed the 9 - month extension All 3 have requested continued expanded access to drug INMB KOL AD January 21, 2021
Slide 6: Biomarker Approach to measuring Neuroinflammation
Biomarker Approach to measuring Neuroinflammation Proteomics Olink® Target 48 Cytokine Free Water White Matter CSF MRI INMB KOL AD January 21, 2021
Slide 7: XPro1595 (1 mg/kg) reduced whole brain neuroinflammation (12 weeks)
-50% -45% -40% -35% -30% -25% -20% -15% -10% -5% 0% MRI CSF XPro1595 (1 mg/kg) reduced whole brain neuroinflammation (12 weeks) WMFW - 4.47% Olink® Target 48 Cytokine
Slide 8: XPro1595 (1 mg/kg) reduced whole brain neuroinflammation (12 weeks)
XPro1595 (1 mg/kg) reduced whole brain neuroinflammation (12 weeks) -50% -45% -40% -35% -30% -25% -20% -15% -10% -5% 0% MRI CSF Olink® Target 48 Cytokine INMB KOL AD January 21, 2021
Slide 9: MRI and CSF measures of inflammation correlate
MRI and CSF measures of inflammation correlate INMB KOL AD January 21, 2021
Slide 10: TMTcalibrator analysis of human CSF with Alzheimer's brain tissue
TMTcalibrator Ρ analysis of human CSF with Alzheimer’s Disease brain tissue trigger White Matter Quality CSF MRI Grey Matter Quality Consequences of reducing Neuroinflammation INMB KOL AD January 21, 2021
Slide 11: Consequences of reducing Neuroinflammation
Consequences of reducing Neuroinflammation TMTcalibrator Ρ AD Brain tissue was analyzed in parallel with CSF from XPro1595 treated patients. Using a high level of AD tissue protein relative to the CSF triggers the mass spectrometer on AD - related peptides and can readily determine whether the same
Slide 12: Significant regulation of AD relevant neuroinflammatory proteins
20 of 26 Targets Significant (P < 0.0001) Synaptic Proteins Contactin - 2 – [ LogFC 1.22] Neurogranin – [ LogFC - 0.56] Neuronal Injury Visinin - like protein 1 (VILIP - 1) – [ LogFC - 0.91] Neurofilament light (NFL) – [ LogFC - 0.84] Immune Chitinase - 3 - like protein 1 (YKL - 40) – [ LogFC 1.85]
Slide 13: The Virtual Biopsy - Measuring Brain Quality
The virtual Biopsy – Measuring Brain quality White Matter Gray Matter Diseased Apparent fiber density (AFD) A measure of White matter quality Healthy Diseased Healthy Cortical Disarray Measurement (CDM) A measure of Gray Matter quality INMB KOL AD January 21, 2021
Slide 14: The Virtual Biopsy - Measuring Gray Matter Quality
The virtual Biopsy – Measuring Gray Matter Quality Baseline 3 months 6 months 9 months ▪ Metric: Cortical Disarray Measurement (CDM) ▪ Improvement (Green) within 3 months ( Yellow – no change) ▪ Continued improvement over 9 months ▪ Improvement was observed in brain regions critically involved in De
Slide 15: The Virtual Biopsy - Measuring White Matter Quality
The virtual Biopsy – Measuring White Matter Quality INMB KOL AD January 21, 2021 Baseline 3 months 6 months 9 months ▪ Metric: Apparent Fiber Density (AFD) ▪ Improvement within 3 months (all non purple color) that peaked at 6 months ▪ Improvement was observed in 31 of 33 fiber bundles associated wit
Slide 16: Assessing Cognition
Assessing Cognition ▪ Challenge: Small N, disease status heterogeneity, short time period ▪ Assessments administered: ▪ Cognitive: MMSE, Verbal Fluency Test, Digit Symbol Coding ▪ Neuropsychiatric Inventory ▪ Bristol Activities of Daily Living Scale ▪ To compare across patients of different disease
Slide 17: Greatest cognitive improvement had largest reduction in neuroinflammation
INMB KOL AD January 21, 2021 Patients with the greatest improvement in cognition had the largest and most reliable reduction in neuroinflammation
Slide 18: Summary
Summary ▪ XPro1595 reduces neuroinflammation across multiple measures and assays ▪ Pathway analyses show a significant effect of XPro1595 in AD relevant pathways and corroborated by novel MRI metrics ▪ XPro1595 significantly reduced markers of neuroinflammation, neural injury, improved synaptic prot
Slide 19: Q&A
Q&A XPro1595 Alzheimer’s KOL event Jan 21, 2021
Slide 20: Leveraging AI to optimize biomarkers
Leveraging AI to optimize biomarkers INMB KOL AD January 21, 2021
Slide 21: Proteomics and AI show XPro1595 normalizes patient biochemistry
Exploratory observation using proteomics and AI show that XPro1595 Causes Patient’s Biochemistry To Safely Normalize 6 Patients Begin XPro1595 INMB KOL AD January 21, 2021